drugset / Trial / NCT03349424

Somatostatin Prevent Post-operation Pancreatic Fistula in Intermediate Risk Patients After Pancreaticoduodenectomy

NCT03349424

Phase 4 Completed 205 enrolled Peking Union Medical College Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to assess the preventive effects of somatostatin on post-operation pancreatic fistula in intermediate risk patients after pancreaticoduodenectomy. Patients assigned into the treatment group will be continuous intravenous infusion with the somatostatin (Stilamin®) in addition to conventional treatments (including infection prevention, nutrition support and acid suppression therapy, etc.).The pancreatic fistula incidence will be monitored within 30 days after operation.

Timeline

Start
2018-06-22
Primary completion
2019-05-24
Completion
2019-05-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatostatin Traditional medicine (herbal / TCM) 250 ug Intravenous

Indications